News
The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...
Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...
The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...
New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...
This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...
Merck KGaA is in the investment-grade market Tuesday, a day after holding investor calls, to help fund its $3.9 billion ...
IO Biotech said on Monday its experimental combination vaccine for a type of skin cancer helped slow the disease's ...
The pharmaceutical giant's journey with Celonis has evolved from operational efficiency to enabling enterprise AI ...
Merck in 2019 inked a deal to evaluate the combination of its blockbuster cancer drug Keytruda with Pacdev from Astellas and Seagen, which Pfizer acquired in a $43 billion deal that closed in late ...
Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...
Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...
Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results